3种中成药辅助治疗非小细胞肺癌的有效性及经济学评价

摘要

OBJECTIVE:To evaluate the clinical efficacy of three Chinese patent medicines added to chemotherapy for non-small cell lung cancer(NSCLC). METHODS:240 patients with NSCLC admitted to our hospital from January 2013 to Janu-ary 2014 were randomly divided into four groups,of 60 cases each,with control group given DP chemotherapy alone,group A,B and C given add-on Compound cantharidin capsule,Shenyi capsule,Zilongjin tablets,respectively plus chemotherapy. The effica-cy,toxicity and cost-effectiveness ratio in the four groups were compared. RESULTS:The total effective rates in the control group,group A,B and C were 33.3%,56.7%,43.3% and 53.3%,respectively(P0.05). Myelosuppression was the major toxicity,followed by nausea and vomiting. The cost-effectiveness ratio in group A was better than in the other three groups. CONCLUSIONS:Compound cantharidin capsule,Shenyi capsule,Zilongjin tablets added to chemotherapy are safe and effective for NSCLC,especially for Compound cantharidin capsule,which is more effective and safer than did Shenyi capsule or Zilongjin tablets,cheap and economical hence is worthy of clinical recommendation.%目的：对比3种抗癌中成药用于非小细胞肺癌（NSCLC）辅助化疗的临床效果。方法：将2013年1月至2014年1月我院收治的NSCLC患者240例，随机分为4组，每组各60例。对照组采取DP化疗方案；在此化疗方案基础上，A组给予复方斑蝥胶囊、B组给予参一胶囊、C组给予紫龙金片。对4组的疗效、毒副反应、成本-效果比进行比较分析。结果：对照组、A组、B组、C组的总有效率分别为33.3％、56.7％、43.3％、53.3％，4组总有效率组间比较差异有统计学意义（P＜0.05）；A组、C组的有效率均明显高于对照组，差异有统计学意义（P＜0.05）；A组的有效率高于B组、C组，但差异无统计学意义（P＞0.05）。毒副反应主要为骨髓抑制，其次为恶心、呕吐。A组的成本-效果比优于其他3组。结论：复方斑蝥胶囊、参一胶囊、紫龙金片用于NSCLC辅助化疗均具有较好的疗效，且毒副反应少；复方斑蝥胶囊比其他2种中成药的疗效更好、毒副反应更少，且价廉、经济，值得推广应用。